Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam

被引:22
|
作者
Di Pilato, Vincenzo
Principe, Luigi [1 ]
Andriani, Lilia [2 ]
Aiezza, Noemi [3 ]
Coppi, Marco [3 ,4 ,6 ]
Ricci, Silvia [2 ]
Giani, Tommaso [3 ,4 ,6 ]
Luzzaro, Francesco [1 ]
Rossolini, Gian Maria [3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Genoa, Italy
[2] S Giovanni Dio Hosp, Clin Pathol & Microbiol Unit, Crotone, Italy
[3] A Manzoni Hosp, Clin Microbiol & Virol Unit, Lecce, Italy
[4] Moriggia Pelascini Gen Hosp, Clin Pathol & Microbiol Unit, Gravedona, Italy
[5] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[6] Florence Careggi Univ Hosp, Clin Microbiol & Virol Unit, Florence, Italy
[7] Univ Firenze, Azienda Ospedaliera Univ Careggi, Dipartimento Med Sperimentale & Clin, SOD Microbiol & Virol, Largo Brambilla, I-50134 Florence, Italy
关键词
beta-lactamase inhibitor combinations; Carbapenemase-producing Enterobacterales; Imipenem/relebactam; Meropenem/vaborbactam; Resistance mechanism; OmpK36;
D O I
10.1016/j.cmi.2022.11.011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Carbapenemase-producing Enterobacterales represent a major cause of difficult-to-treat infections world-wide. Novel beta-lactam/Enterobacterales-lactamase inhibitor combinations, including ceftazidime/avibactam (CZA), meropenem/vaborbactam (MVB), and imipenem/relebactam (IMR), represented a breakthrough in the treatment of some carbapenemase-producing Enterobacterales infections. However, acquired resistance to these agents has been reported in Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales. Herein, we reported an outbreak caused by CZA-resistant, KPC-producing Klebsiella pneumoniae (KPC-Kp), which was also variably resistant to carbapenem-based beta-lactam/beta-lactamase inhibitor combinations. Methods: Bacterial isolates were subjected to antimicrobial susceptibility testing, whole-genome sequencing, determination of bla(KPC) gene dosage, and analysis of carbapenemase activity. Results: Overall, 15 KPC-Kp, nine CZA-resistant (CZA(R)), and six CZA-susceptible isolates were collected from an outbreak involving six patients in a neurorehabilitation facility. Of the nine CZA(R) isolates, seven were also resistant to MVB and one was also resistant to IMR. Whole-genome sequencing revealed that the outbreak was multi-clonal, with CZA(R) KPC-Kp belonging to the ST101, ST1519, and two ST512 sublineages, which were involved in two independent transmission clusters. Resistance to CZA was primarily mediated by overproduction of KPC-3 associated with increased gene dosage, a mechanism accounting for cross-resistance to MVB in most cases, and to IMR in a single KPC-Kp isolate; multiple OmpK36 aletarions were also detected. Mutated KPC (KPC-53) was detected in a single case. Positivity for CZA(R) KPC-Kp was inconstantly associated with previous CZA exposure. Conclusions: In this multi-clonal outbreak of KPC-Kp, the overproduction of KPC-3 was the leading mechanism of cross-resistance to CZA and MVB, whereas resistance to IMR appeared less affected. The emergence and dissemination of similar resistance mechanisms may have relevant clinical and diagnostic implications, and their surveillance is warranted. (c) 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:537e1 / 537e8
页数:8
相关论文
共 50 条
  • [1] Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae
    Davido, Benjamin
    Cremieux, Anne-Claude
    Vaugier, Isabelle
    Gatin, Laure
    Noussair, Latifa
    Massias, Laurent
    Laurent, Frederic
    Saleh-Mghir, Azzam
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 61 (01)
  • [2] Clinical and Microbiological characteristics of patients with ceftazidime/avibactam-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains
    Szu-Yu Liu
    Sheng-Hua Chou
    Chien Chuang
    Chih-Han Juan
    Yu-Chien Ho
    Hsiang-Ling Ho
    Liang Chen
    Yi-Tsung Lin
    Annals of Clinical Microbiology and Antimicrobials, 24 (1)
  • [3] Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin
    Kontopoulou, K.
    Protonotariou, E.
    Vasilakos, K.
    Kriti, M.
    Koteli, A.
    Antoniadou, E.
    Sofianou, D.
    JOURNAL OF HOSPITAL INFECTION, 2010, 76 (01) : 70 - 73
  • [4] Ceftazidime-avibactam based combinations against carbapenemase producing Klebsiella pneumoniae harboring hypervirulence plasmids
    Bulman, Zackery P.
    Tan, Xing
    Chu, Ting-Yu
    Huang, Yanqin
    Rana, Amisha P.
    Singh, Nidhi
    Flowers, Stephanie A.
    Kyono, Yasuhiro
    Kreiswirth, Barry N.
    Chen, Liang
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 3946 - 3954
  • [5] Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization
    Gaibani, P.
    Re, M. C.
    Campoli, C.
    Viale, P. L.
    Ambretti, S.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (04) : 516.e1 - 516.e4
  • [6] Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series
    van Asten, S. A., V
    Boattini, M.
    Kraakman, M. E. M.
    Bianco, G.
    Iannaccone, M.
    Costa, C.
    Cavallo, R.
    Bernards, A. T.
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (05) : 778 - 780
  • [7] Emergence of transferable ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae due to a novel CMY AmpC β-lactamase in China
    Xu, Min
    Zhao, Jun
    Xu, Li
    Yang, Qing
    Xu, Hao
    Kong, Haishen
    Zhou, Jianying
    Fu, Yiqi
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (01) : 136.e1 - 136.e6
  • [8] Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature
    Shields, Ryan K.
    Hong Nguyen, M.
    Press, Ellen G.
    Chen, Liang
    Kreiswirth, Barry N.
    Clancy, Cornelius J.
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (03): : 1 - 4
  • [9] Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase
    Bovo, Federica
    Amadesi, Stefano
    Palombo, Marta
    Lazzarotto, Tiziana
    Ambretti, Simone
    Gaibani, Paolo
    JAC-ANTIMICROBIAL RESISTANCE, 2023, 5 (04):
  • [10] Carbapenem-resistant Klebsiella pneumoniae outbreak with monoclonal spread: Evaluation of resistance genes and ceftazidime-avibactam susceptibility
    Arici, Neslihan
    Tanriverdi, Elif Seren
    Calik, Seyma
    Kansak, Nilgun
    Adaleti, Riza
    Otlu, Baris
    Aksaray, Sebahat
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2023, 46